C172H265N43O51
3751 g/mol
Aktif Farmasötik İngredientUyarı
Liraglutide
CAS204656-20-2
Kategori
Aktif Farmasötik İngredient
Bileşik Sınıfı
Peptit
Birincil Kullanım
Farmasötik ham madde
Liraglutide is a pharmaceutical raw material used in the manufacturing of anti-diabetic medications. It is a synthetic peptide compound consisting of 33 amino acids with a fatty acid side chain, designed for use in research and production of treatments targeting type 2 diabetes and obesity.
active pharmaceutical ingredient for anti-diabetic formulationsresearch compound for metabolic disease studies
İçerik kapsamı: Bu sayfadaki bilgiler kimyasal tanımlama ile endüstriyel tedarik, araştırma ve üretim bağlamlarına ilişkindir. Tedavi iddiası, tıbbi tavsiye veya ilaç kullanım talimatı niteliği taşımaz.
Bu bileşiği tedarik ediyor veya sağlıyor musunuz?
Envanterinizi listeleyin veya satın alma talebi gönderin
CAS 204656-20-2
İlgili Bileşikler
GüçlüBenzer yapıBenzerlik 0.87
Glucagon-like peptide 1 (1-37)
CAS87805-34-3
active pharmaceutical ingredient
BenzerBenzer yapıBenzerlik 0.84
Semaglutid
CAS910463-68-2
active pharmaceutical ingredient
BenzerBenzer yapıBenzerlik 0.84
GLP-1 (1-36) amide (human, bovine, guinea pig, mouse, rat) trifluoroacetate salt H-His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH2 trifluoroacetate salt
CAS99658-04-5
active pharmaceutical ingredient
BenzerBenzer yapıBenzerlik 0.76
Teduglutide
CAS197922-42-2
active pharmaceutical ingredient
ReferansAynı kategori
Valerianol
CAS20489-45-6
plant metabolite reference standard
ReferansAynı kategori
(R,R)-Epoxy Leucine Carfilzomib
CAS2049025-76-3
proteasome inhibitor impurity reference standard
ReferansAynı kategori
Quinapyramine
CAS20493-41-8
veterinary trypanocidal agent
ReferansAynı kategori
Upadacitinib hemihydrate
CAS2050057-56-0
active pharmaceutical ingredient
Güvenlik Referansı
Uyarı
H351Suspected of causing cancer
H361Suspected of damaging fertility or the unborn child
Tanımlayıcılar
IUPAC Adı
(2S)-5-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-(hexadecanoylamino)-5-oxopentanoic acid
InChIKey
YSDQQAXHVYUZIW-QCIJIYAXSA-N
SMILES
CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)N)C(=O)O
Eş Anlamlılar (19)
- Liraglutida [INN-Spanish]
- Liraglutidum [INN-Latin]
- Liraglutida
- Liraglutide
- Liraglutide (rDNA origin)
- Liraglutide recombinant
- Liraglutidum
- NNC 90-1170
- Saxenda
- victoza